Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification

Rheumatology
Samuel DeshayesAchille Aouba

Abstract

In ANCA-associated vasculitis (AAV), classifications have emerged to individualize homogeneous clinical and outcomes patterns, including the recently defined anti-MPO granulomatosis with polyangiitis (GPA) subgroup. This study aimed to retrospectively evaluate the impacts of re-classification based on clinicopathological criteria and/or ANCA specificity. A retrospective monocentric study conducted at Caen University Hospital led to the identification of PR3 or MPO-ANCA AAV patients from January 2000 or September 2011, respectively, to June 2016. Eosinophilic GPA patients were excluded. AAVs were thereby also classified either as GPA or microscopic polyangiitis (MPA) according to the European Medicines Agency vasculitis algorithm. A total of 150 AAV patients were included (94 GPA, 56 MPA; 87 anti-PR3 and 63 anti-MPO patients). GPA patients exhibited a worse relapse-free survival but a better renal survival (P < 0.001 and P = 0.021, respectively) than MPA patients. Overall, relapse-free and renal survival rates were similar between anti-PR3 and anti-MPO patients (P = 0.35, 0.17 and 0.15, respectively). Similarly, the prognosis was identical between anti-MPO MPA patients and anti-PR3 MPA patients (P = 0.33, 0.19 and 0.65, respecti...Continue Reading

References

Jan 1, 1995·Kidney International·C F FranssenS J Hoorntje
Jan 5, 2002·Annals of the Rheumatic Diseases·R A WattsG A Bentham
Aug 6, 2002·Controlled Clinical Trials·UNKNOWN WGET Research Group
Aug 9, 2003·Arthritis and Rheumatism·John H Stone, UNKNOWN Wegener's Granulomatosis Etanercept Trial Research Group
Sep 19, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Min ChenHai-Yan Wang
Apr 9, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Deana D HogansonClement J Michet
Dec 5, 2008·Annals of the Rheumatic Diseases·C MukhtyarR A Luqmani
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group
Nov 27, 2010·Annals of the Rheumatic Diseases·Oliver FlossmannUNKNOWN European Vasculitis Study Group
Sep 29, 2011·Arthritis and Rheumatism·Michael WalshUNKNOWN European Vasculitis Study Group
Jul 20, 2012·The New England Journal of Medicine·Paul A LyonsKenneth G C Smith
Sep 11, 2012·Annals of the Rheumatic Diseases·Alfred MahrUNKNOWN French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS)
Oct 10, 2012·Arthritis and Rheumatism·J C JennetteR A Watts
Jul 13, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Anoek A E de JoodeCoen A Stegeman
Jan 17, 2014·The Journal of Rheumatology·Shunsuke FurutaDavid Jayne
Apr 22, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Luis F QuintanaDavid Jayne
Apr 24, 2014·International Urology and Nephrology·Ágnes HarisIstván Mucsi
Jul 30, 2014·Modern Rheumatology·Yumi TsuchidaKazuhiko Yamamoto
Oct 8, 2015·Annals of the Rheumatic Diseases·Chinar RahmattullaIngeborg M Bajema
Dec 2, 2015·Annals of the Rheumatic Diseases·Sebastian UnizonyUNKNOWN RAVE-ITN Research Group
Feb 23, 2017·Medicine·Roser Solans-LaquéUNKNOWN Spanish Registry of systemic vasculitis (REVAS) from the Autoimmune Diseases Study Group (GEAS) of the Spanish Society of In
Apr 26, 2018·Arthritis & Rheumatology·Sung Kweon ChoSeungho Ryu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.